Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
Author:
Publisher
Frontiers Media SA
Subject
Cancer Research,Oncology
Reference71 articles.
1. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond;Quintàs-Cardama;Nat Rev Drug Discov.,2011
2. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium;Griesshammer;Expert Opin Pharmacother.,2017
3. Somatic mutations of calreticulin in myeloproliferative neoplasms;Klampfl;N Engl J Med.,2013
4. The role of new technologies in myeloproliferative neoplasms;Palumbo;Front Oncol.,2019
5. Immunological consequences of JAK inhibition: friend or foe?;McLornan;Curr Hematol Malig Rep.,2015
Cited by 156 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Tetrastigma hemsleyanum polysaccharides alleviate imiquimod-induced psoriasis-like skin lesions in mice by modulating the JAK/STAT3 signaling pathway;Phytomedicine;2024-10
2. Immune‐dysregulation harnessing in myeloid neoplasms;Cancer Medicine;2024-09
3. Ruxolitinib: a game changer in paediatric chronic graft-versus-host disease management?;The Lancet Haematology;2024-08
4. The effectiveness of ruxolitinib and cyclophosphamide combination on T helper 17 and regulatory T cells in rat experimental membranous glomerulonephritis;Molecular and Cellular Probes;2024-08
5. Targeting VEGF-mediated blood-brain barrier disruption in advanced cerebral leukodystrophy;Journal of Neuroimmunology;2024-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3